{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013054","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.059963+00:00","generated_at":"2026-06-24T01:19:51.558604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Capricor Q2 net loss $7.1M; CAP-1002 Phase 3 trial underway, cash $51.4M","bullets":["Net loss $7.1M ($0.29/share) vs $4.7M ($0.21/share) in Q2 2021.","Cash & equivalents $51.4M at June 30, 2022, up from $34.9M at Dec. 31, 2021.","First patient dosed in HOPE-3 pivotal Phase 3 trial of CAP-1002 for late-stage Duchenne muscular dystrophy.","Positive one-year HOPE-2 OLE data showed statistically significant skeletal muscle improvement (PUL v2.0, p=0.02).","Requesting FDA meeting to discuss CAP-1002 approval pathway; cash runway into Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013054","json":"https://secwatch.observer/filing/0001558370-22-013054.json","markdown":"https://secwatch.observer/filing/0001558370-22-013054.md","text":"https://secwatch.observer/filing/0001558370-22-013054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022013054/0001558370-22-013054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837022013054/capr-20220810x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:19:51.558604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}